Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
-
1
All 16 patients treated with the individualized cancer vaccine remained disease-free after a median follow-up of 41 months.
-
2
Three of the 16 patients in the control group experienced disease recurrence during the study.
-
3
The trial focused on patients with resected, human papillomavirus-negative head and neck squamous cell carcinoma.
-
4
The vaccine, TG4050, is tailored for each patient using tumor and normal tissue samples to identify cancer-specific mutations.
-
5
The vaccine induced detectable T-cell responses in 73.3% of evaluated patients, with responses lasting over a year after treatment.
